Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2018: ¥7,280,000 (Direct Cost: ¥5,600,000、Indirect Cost: ¥1,680,000)
|
Outline of Final Research Achievements |
Adoptive T cell therapy using TCR-modified T cells is a promising next-generation immunotherapy. However, it was not easy to isolate a functional TCR, and to analyze the reactivity and predict the side effects. In this study, we have established a method to obtain TCRs that respond to the original cancer cells from tumor-infiltrating lymphocytes, and technically simple method to generate functional p/MHC that analyze the reactivity of TCRs. These results may contribute to development of adoptive T cell therapy using TCR-modified T cells.
|